Will MetLife Egypt and AXA Egypt cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Augtyro is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDA?

The EDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Egyptian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Egyptian Medical Syndicate and the EDA verifies the active license; the EDA application records both the prescribing physician and the dispensing facility.

Can I receive Augtyro at home?

The dispensing facility must be Egyptian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 19,000 to 22,000 per month. Delivered quote within 24h.Get my quote

Augtyro access in Egypt: the EDA named-patient pathway

How patients in the Arab Republic of Egypt legally obtain Augtyro (repotrectinib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Egypt access Augtyro (repotrectinib) for ROS1-positive locally advanced or metastatic non-small cell lung cancer and NTRK-positive locally advanced or metastatic solid tumors through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Augtyro reaches patients in Egypt

Augtyro (repotrectinib, a next-generation oral ROS1 and NTRK tyrosine kinase inhibitor designed to retain activity against common acquired resistance mutations including the ROS1 G2032R solvent-front mutation, from Bristol Myers Squibb) received US FDA approval in November 2023 for ROS1-positive locally advanced or metastatic non-small cell lung cancer in adults, and a tumour-agnostic accelerated approval in June 2024 for NTRK gene fusion-positive locally advanced or metastatic solid tumours in adult and paediatric patients aged 12 years and older per the FDA label record at accessdata.fda.gov/scripts/cder/daf. The Egyptian Drug Authority registered-drug database at eservices.edaegypt.gov.eg shows no public registration record for repotrectinib or Augtyro as of 2026-06-01. Egyptian patients access the drug through the Personal Importation of Unregistered Medicines pathway under Pharmacy Practice Law No. 127 of 1955, Health Minister Decree No. 296 of 2009, and the post-2019 EDA framework at edaegypt.gov.eg. The treating Egyptian-licensed thoracic oncologist or solid-tumour oncologist issues a stamped medical report documenting tissue or liquid-biopsy confirmation of a ROS1 fusion or NTRK1/2/3 fusion (next-generation sequencing or FISH report attached), prior TKI exposure if any (crizotinib, entrectinib, larotrectinib), the planned dosing schedule of 160 mg orally once daily for 14 days then 160 mg twice daily, and the rationale referencing the TRIDENT-1 phase 1/2 trial at clinicaltrials.gov/NCT03093116. EDA does not publish a fixed processing-time SLA; reporting indicates one to three weeks when documentation is complete. Each shipment requires a fresh permit with convention up to a three-month supply per application; chronic-therapy oncology patients re-file per cycle.

Where Augtyro is dispensed in Egypt

Augtyro is an oral targeted therapy administered in the outpatient thoracic-oncology or molecular-oncology setting with CT response assessment every 6 to 8 weeks, full blood count, liver function, and ECG monitoring for QT-related signals. The Egyptian tertiary centres with thoracic oncology service lines and molecular-profiling infrastructure include the National Cancer Institute at Cairo University, with a Medical Oncology and Thoracic Oncology service and the country's principal academic molecular pathology lab at nci.cu.edu.eg; Cairo University Hospitals (Kasr Al-Ainy) Department of Clinical Oncology at kasralainy.edu.eg; Ain Shams University Hospitals Department of Clinical Oncology in Cairo; Mansoura University Hospitals Oncology Centre (OCMU) at mans.edu.eg; and Alexandria University Hospitals Department of Clinical Oncology. Cleopatra Hospitals Group at cleopatrahospital.com and As-Salam International Hospital in Cairo handle private-sector thoracic-oncology cases with named-patient specialty drug imports. NCI Cairo is the most frequent dispensing node for first-in-Egypt NTRK and ROS1 targeted therapy because it runs the molecular workup in-house and integrates with the regional thoracic-oncology multidisciplinary boards.

What Augtyro costs in Egypt

The US wholesale acquisition cost for Augtyro is reported by Bristol Myers Squibb at approximately USD 24,000 to USD 26,000 per 30-day supply at the maintenance dose of 160 mg twice daily, with annual drug-only spend in the range of USD 290,000 to USD 315,000 at maintenance per manufacturer disclosures tracked through Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. The first 14-day lead-in at 160 mg once daily has a proportionally lower cost. Price snapshot: 2026-06-01. No public local-currency price for Augtyro in Egyptian Pounds is observed in the EDA pricing committee output or the Unified Procurement Authority disclosures at upa.gov.eg as of 2026-06-01; do not estimate. The Central Bank of Egypt USD reference rate has been volatile through 2024 to 2026; families wiring in USD avoid intra-process FX exposure. Cost layers beyond the drug include ambient logistics (Augtyro is a room-temperature oral capsule and does not require cold chain), the nominal EDA permit and customs duties, the dispensing facility administration fees, and the Reserve Meds concierge fee itemised separately on every firm quote.

Funding and access barriers for Augtyro in Egypt

Targeted oncology funding for ROS1- and NTRK-driven cancers in Egypt is biomarker-gated and case-by-case. The Universal Health Insurance Authority (UHIA) at uhia.gov.eg covers oncology indications in implementation governorates per the joint HTA process with the Unified Procurement Authority; repotrectinib is not on the published UHIA reimbursement list as of 2026-06-01, and the precedents from prior ROS1 TKIs (crizotinib, entrectinib) indicate UHIA assessment proceeds case by case rather than as a standing entitlement. The Treatment at State Expense scheme (Nafaqat Ala Al-Dawla) administered through MOHP funds case-by-case adult oncology treatment for Egyptian nationals lacking means, and has been used for prior-generation ROS1 inhibitors. NCI Cairo and the university oncology centres have institutional access to compassionate-use channels with manufacturers for biomarker-positive cases. Major private insurers (MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance, GlobeMed Egypt as TPA, Med Net) typically exclude or sub-limit unregistered named-patient imports on retail policies; corporate group plans may include with prior authorisation and documented biomarker positivity plus prior-TKI exposure. Out-of-pocket spending dominates per World Bank data at data.worldbank.org, and for adult oncology named-patient imports the dominant pattern is self-pay supplemented by Treatment at State Expense and family fundraising. Access to ROS1 and NTRK molecular testing remains a binding step that families and centres plan around because Augtyro eligibility is biomarker-defined.

Recent regulatory and access news for Augtyro

The FDA expanded the Augtyro label in June 2024 with the tumour-agnostic accelerated approval for NTRK gene fusion-positive solid tumours in adults and paediatric patients aged 12 years and older per the FDA Drugs@FDA listing at accessdata.fda.gov/scripts/cder/daf; this widens the eligible-patient pool an Egyptian physician can cite. The European Medicines Agency authorised Augtyro for ROS1-positive NSCLC in October 2024 with the European Public Assessment Report at ema.europa.eu/medicines/human/EPAR/augtyro, providing a second reference-authority anchor for Egyptian EDA personal-import filings. UHIA and the Unified Procurement Authority continued the phased UHI rollout across governorates per UHIA bulletins at uhia.gov.eg. No drug-specific EDA bulletin for Augtyro or repotrectinib over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Augtyro cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Augtyro specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Augtyro case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Augtyro is a next-generation ROS1/NTRK TKI designed to maintain activity against common acquired resistance mutations; named-patient files document the specific ROS1 fusion or NTRK fusion identified on molecular testing and any prior TKI exposure. Egypt thoracic oncology programmes increasingly run upfront molecular profiling that supports this case-build.

Next step

If your Egyptian physician has prescribed Augtyro and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Augtyro case Or message us on WhatsApp